William E. Martin's most recent trade in Maravai LifeSciences Holdings Inc - Ordinary Shares - Class A was a trade of 986,194 Class A Common Stock done . Disclosure was reported to the exchange on March 17, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Maravai LifeSciences Holdings Inc (Class A) | William E. Martin | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2025 | 986,194 | 1,814,643 | - | - | Class A Common Stock | |
| Maravai LifeSciences Holdings Inc (Class A) | William Martin E. | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.56 per share. | 15 Jan 2025 | 160,981 | 828,449 | - | 4.6 | 734,073 | Class A Common Stock |
| Inozyme Pharma Inc | Martin William Edwards | Director | 18 Jun 2024 | 28,000 | 28,000 | - | - | Stock Option (right to buy) | ||
| Morphic Holding Inc | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 23,168 | 23,168 | - | - | Common Stock | |
| Inozyme Pharma Inc | Martin William Edwards | Director | 13 Jun 2023 | 16,000 | 16,000 | - | - | Stock Option (right to buy) | ||
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 2,137 | 2,137 | - | - | Stock Option (right-to-buy) | |
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 93.61 per share. | 07 Jun 2023 | 1,682 | 6,116 (0%) | 0% | 93.6 | 157,452 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 169 | 169 | - | - | Stock Option (right-to-buy) | |
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 93.61 per share. | 07 Jun 2023 | 133 | 4,434 (0%) | 0% | 93.6 | 12,450 | Class A common stock |
| Morphic Holding Inc | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 12,535 | 12,535 | - | - | Director Stock Option (Right to Buy) | |
| Inozyme Pharma Inc | Martin William Edwards | Director | 10 Jun 2022 | 9,367 | 9,367 | - | - | Stock Option (right to buy) | ||
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 5,620 | 5,620 | - | - | Stock Option (right-to-buy) | |
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 34.76 per share. | 08 Jun 2022 | 3,883 | 4,301 (0%) | 0% | 34.8 | 134,973 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 520 | 520 | - | - | Stock Option (right-to-buy) | |
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 34.76 per share. | 08 Jun 2022 | 359 | 418 (0%) | 0% | 34.8 | 12,479 | Class A common stock |
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 99 | 99 | - | - | Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 27.32 per share. | 03 Jan 2022 | 59 | 59 (0%) | 0% | 27.3 | 1,612 | Class A common stock |
| KalVista Pharma Inc | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 10,000 | 10,000 | - | - | Director Stock Option (Right to Buy) | |
| Inozyme Pharma Inc | Martin William Edwards | Director | 23 Jun 2021 | 9,367 | 9,367 | - | - | Stock Option (right to buy) | ||
| Morphic Holding Inc | Martin William Edwards | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 12,000 | 12,000 | - | - | Director Stock Option (right to buy) |